A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Alejandra Bruna et al.|EMBO Molecular Medicine|2018Cited by 271
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancerElena Élez, Rodrigo A. Toledo, Javier Ros et al.|Nature Medicine|2022Cited by 111
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerMercedes Marín‐Aguilera, Laia Paré, Pedro Jares et al.|ESMO Open|2024Cited by 27
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Alice Durand, Virginia Pubul et al.|BMC Cancer|2025Cited by 7